Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study

Metastatic uveal melanoma has poor overall survival (OS) and no approved systemic therapy options. Studies of single-agent immunotherapy regimens have shown minimal benefit. There is the potential for improved responses with the use of combination immunotherapy. PATIENTS AND METHODS: We conducted a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Pelster, Meredith S., Gruschkus, Stephen K., Bassett, Roland, Gombos, Dan S., Shephard, Michael, Posada, Liberty, Glover, Maura S., Simien, Rinata, Diab, Adi, Hwu, Patrick, Carter, Brett W., Patel, Sapna P.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2021
Gaiak:
Original Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8257877/
https://ncbi.nlm.nih.gov/pubmed/33125309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00605
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak